Onkologie. 2019:13(4):150-156 | DOI: 10.36290/xon.2019.029
New treatment options in hormone-sensitive prostate cancer
- Urologická klinika VFN a 1. LF UK v Praze
The main aim of the treatment of metastatic prostate cancer (mPC) is to lower the value of testosterone to the castration level. Androgen deprivation therapy (ADT) leads initially to a reduction of the level of prostate–specific antigen and/or to radiographic and clinical response. The combination of docetaxel chemotherapy or new hormone agents (abiraterone acetate, enzalutamide, apalutamide, darolutamide) in the first line treatment of mPC may lead to an increase in overall survival or time to radiographic progression. This article assesses the results of available studies and in conclusion it reviews which combination is the most appropriate for individual patient. We also recommend to read, among others, the last paragraph of this publication, which deals with the choice of appropriate first–line mPC medications.
Keywords: metastatic hormone-sensitive prostate cancer, docetaxel, abiraterone, enzalutamide, darolutamide, apalutamide
Published: September 15, 2019 Show citation
References
- EAU-EANM-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-2019.http://uroweb.org/ guideline/prostate-cancer. Přístup dne 13. 7. 2019.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502-12.
Go to original source... 
Go to PubMed... - Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15): 1513-20. Go to original source... Go to PubMed...
- Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; (2): 149-58. Go to original source... Go to PubMed...
- Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8): 737-46. Go to original source... Go to PubMed...
- James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-77. Go to original source... Go to PubMed...
- Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4): 352-360. Go to original source... Go to PubMed...
- James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017; 377(4): 338-351. Go to original source... Go to PubMed...
- Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97. Go to original source... Go to PubMed...
- Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5): 424-33. Go to original source... Go to PubMed...
- Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018; 378: 2465-74. Go to original source... Go to PubMed...
- Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jun 2. [Epub ahead of print]. Go to original source... Go to PubMed...
- Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. J Clin Oncol 37, 2019 (suppl 7S; abstr 687). Go to original source...
- Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-1418. Go to original source... Go to PubMed...
- Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol. 2019; 20(2): 14. Go to original source... Go to PubMed...
- Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019; 381(1): 13-24. Go to original source... Go to PubMed...
- Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019; 380(13): 1235-1246. Go to original source... Go to PubMed...
- Smith MR, Saad F, Hussain M, et al. ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 36, 2018 (suppl 6; abstr TPS383) Go to original source...
- Souhrn údajů o přípravku. https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_cs.pdf. Přístup dne 15. 7. 2019.
- Souhrn údajů o přípravku. https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_cs.pdf. Přístup dne 15. 7. 2019.